Spero Therapeutics, Inc. Financing Cash Flow
Spero Therapeutics, Inc. (SPRO) reported Financing Cash Flow of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2025-03-27
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2023-12-31 was $1.00K, a 99.99% decline year-over-year.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2023-09-30 was $220.00K, a 96.41% decline year-over-year.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2023-06-30 was $0.00.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $221.00K.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$29.55M, a 135.16% decline from fiscal 2021.
- Spero Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $84.05M, a 35.78% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $221.00K derived: sum of 2 quarters · filed 2025-03-27 | $221.00K derived: sum of 3 quarters · filed 2025-03-27 | $221.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $220.00K derived: sum of 2 quarters · filed 2024-11-14 | $220.00K 10-Q · filed 2024-11-14 | $14.40M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $14.18M derived: sum of 3 quarters · filed 2024-03-13 | $20.31M derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $14.18M derived: sum of 2 quarters · filed 2024-03-13 | $20.31M derived: sum of 3 quarters · filed 2024-03-13 | -$33.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | $14.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $20.31M derived: sum of 2 quarters · filed 2024-03-13 | -$33.37M derived: sum of 3 quarters · filed 2024-03-13 | -$29.55M 10-K · filed 2024-03-13 |
| 2022-09-30 | $6.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$47.55M derived: sum of 2 quarters · filed 2023-11-13 | -$43.73M 10-Q · filed 2023-11-13 | $6.62M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$53.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$49.86M 10-Q · filed 2023-08-10 | $486.00K derived: sum of 3 quarters · filed 2023-08-10 | $29.71M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $3.81M 10-Q · filed 2023-05-11 | $54.16M derived: sum of 2 quarters · filed 2023-05-11 | $83.39M derived: sum of 3 quarters · filed 2023-05-11 | $83.56M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $50.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $79.57M derived: sum of 2 quarters · filed 2023-03-30 | $79.74M derived: sum of 3 quarters · filed 2023-03-30 | $84.05M 10-K · filed 2023-03-30 |
| 2021-09-30 | $29.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $29.39M derived: sum of 2 quarters · filed 2022-11-14 | $33.70M 10-Q · filed 2022-11-14 | $49.79M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.48M 10-Q · filed 2022-08-10 | $20.57M derived: sum of 3 quarters · filed 2022-08-10 | $97.78M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.31M 10-Q · filed 2022-05-16 | $20.40M derived: sum of 2 quarters · filed 2022-05-16 | $97.61M derived: sum of 3 quarters · filed 2022-05-16 | $105.00M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $16.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $93.31M derived: sum of 2 quarters · filed 2022-03-31 | $100.69M derived: sum of 3 quarters · filed 2022-03-31 | $130.88M 10-K · filed 2022-03-31 |
| 2020-09-30 | $77.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $84.61M derived: sum of 2 quarters · filed 2021-11-10 | $114.79M 10-Q · filed 2021-11-10 | $120.39M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $7.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $37.58M 10-Q · filed 2021-08-05 | $43.17M derived: sum of 3 quarters · filed 2021-08-05 | $43.19M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $30.19M 10-Q · filed 2021-05-06 | $35.78M derived: sum of 2 quarters · filed 2021-05-06 | $35.80M derived: sum of 3 quarters · filed 2021-05-06 | $44.76M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $5.61M derived: sum of 2 quarters · filed 2021-03-11 | $14.57M derived: sum of 3 quarters · filed 2021-03-11 | $16.14M 10-K · filed 2021-03-11 |
| 2019-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $8.97M derived: sum of 2 quarters · filed 2020-11-05 | $10.54M 10-Q · filed 2020-11-05 | $10.36M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $8.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $10.53M 10-Q · filed 2020-08-06 | $10.35M derived: sum of 3 quarters · filed 2020-08-06 | $80.25M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $1.57M 10-Q · filed 2020-05-08 | $1.39M derived: sum of 2 quarters · filed 2020-05-08 | $71.29M derived: sum of 3 quarters · filed 2020-05-08 | |
| 2018-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $69.72M derived: sum of 2 quarters · filed 2020-03-16 | $69.52M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $69.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $69.70M 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | -$196.00K 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $74.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $74.27M derived: sum of 2 quarters · filed 2019-03-14 | $116.11M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $41.43M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $41.84M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $34.41M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |